Recently, immunotherapy with immune checkpoint inhibitors (ICIs) against PD1/PD-L1 signaling has generated great excitement because of its success in achieving long-term durable responses in patients with metastatic CRC whose tumors are dMMR, in which ICIs antagonize T cell inhibitory signaling, potentiating cytotoxic killing of tumor cells [5,6,8,9,10]. This evidence concerns the gene CD274 and neoplasm.